Page Redirect Alert
The link you are about to visit does not belong to this site, please pay attention to your account security.
https://cts.businesswire.com/ct/CT?id=smartlink&url=https://www.catalym.com/catalym-announces-initial-data-from-ongoing-phase-2a-trial-evaluating-gdf-15-targeting-antibody-visugromab-in-combination-with-nivolumab-at-asco-2023/&esheet=53468510&newsitemid=20230720231828&lan=en-US&anchor=recently presented at ASCO&index=5&md5=72e1968ef72af261f65197438ec2eafd
